MA51288A - Analogues d'incrétine et leurs utilisations - Google Patents
Analogues d'incrétine et leurs utilisationsInfo
- Publication number
- MA51288A MA51288A MA051288A MA51288A MA51288A MA 51288 A MA51288 A MA 51288A MA 051288 A MA051288 A MA 051288A MA 51288 A MA51288 A MA 51288A MA 51288 A MA51288 A MA 51288A
- Authority
- MA
- Morocco
- Prior art keywords
- incretin
- analogues
- incretin analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Details Of Garments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608613P | 2017-12-21 | 2017-12-21 | |
| PCT/US2018/065663 WO2019125938A1 (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
| EP18830618.7A EP3727426B1 (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51288A true MA51288A (fr) | 2021-03-31 |
| MA51288B1 MA51288B1 (fr) | 2026-02-27 |
Family
ID=65003519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51288A MA51288B1 (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US11542313B2 (fr) |
| EP (2) | EP3727426B1 (fr) |
| JP (3) | JP6961838B2 (fr) |
| KR (2) | KR102622642B1 (fr) |
| CN (1) | CN111491658B (fr) |
| AR (1) | AR113486A1 (fr) |
| AU (1) | AU2018388962B2 (fr) |
| BR (1) | BR112020010244A2 (fr) |
| CA (1) | CA3084005C (fr) |
| CL (1) | CL2020001635A1 (fr) |
| CO (1) | CO2020006255A2 (fr) |
| CR (1) | CR20200255A (fr) |
| DK (1) | DK3727426T3 (fr) |
| DO (1) | DOP2020000123A (fr) |
| EA (1) | EA202091290A1 (fr) |
| EC (1) | ECSP20032650A (fr) |
| ES (1) | ES3061179T3 (fr) |
| FI (1) | FI3727426T3 (fr) |
| HR (1) | HRP20260186T1 (fr) |
| IL (2) | IL275468B2 (fr) |
| JO (1) | JOP20200137B1 (fr) |
| LT (1) | LT3727426T (fr) |
| MA (1) | MA51288B1 (fr) |
| MD (1) | MD3727426T2 (fr) |
| MX (2) | MX2020006548A (fr) |
| MY (1) | MY199143A (fr) |
| PE (2) | PE20251598A1 (fr) |
| PH (1) | PH12020551025A1 (fr) |
| PL (1) | PL3727426T3 (fr) |
| PT (1) | PT3727426T (fr) |
| RS (1) | RS67748B1 (fr) |
| SG (1) | SG11202005606VA (fr) |
| SI (1) | SI3727426T1 (fr) |
| SM (1) | SMT202600216T1 (fr) |
| TW (3) | TWI912614B (fr) |
| UA (1) | UA129012C2 (fr) |
| WO (1) | WO2019125938A1 (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| US12257287B2 (en) * | 2018-11-12 | 2025-03-25 | Tianjin Institute Of Pharmaceutical Research Co., Ltd. | Glucagon-derived peptide and use thereof |
| WO2021034815A1 (fr) * | 2019-08-19 | 2021-02-25 | Eli Lilly And Company | Procédés de fabrication d'analogues d'incrétine |
| CN122520749A (zh) * | 2019-12-03 | 2026-08-07 | 安泰博医药 | 优化的gip肽类似物 |
| AR120714A1 (es) | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| WO2022090447A1 (fr) | 2020-10-30 | 2022-05-05 | Novo Nordisk A/S | Agonistes triples du récepteur de glp-1, gip et glucagon |
| CN114685642B (zh) * | 2020-12-29 | 2024-03-29 | 浙江和泽医药科技股份有限公司 | 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| TW202423476A (zh) | 2021-03-23 | 2024-06-16 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| CA3219647A1 (fr) * | 2021-05-26 | 2022-12-01 | The United Bio-Technology (Hengqin) Co., Ltd. | Multiagonistes et utilisation connexe |
| WO2022268029A1 (fr) * | 2021-06-21 | 2022-12-29 | 广东东阳光药业有限公司 | Agoniste triple pour récepteurs glp-1, gcg et gip |
| AU2022298662B2 (en) | 2021-06-23 | 2025-06-05 | Eli Lilly And Company | An incretin analog for use in glycemic control and weight management |
| CA3231953A1 (fr) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions et methodes de traitement de troubles metaboliques et hepatiques |
| TWI828434B (zh) * | 2021-11-19 | 2024-01-01 | 大陸商南京明德新藥研發有限公司 | 釘合肽及其應用 |
| KR20240099485A (ko) * | 2021-11-19 | 2024-06-28 | 메드샤인 디스커버리 아이엔씨. | 스테이플화 펩타이드 및 이의 용도 |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN114957387B (zh) * | 2022-05-18 | 2023-06-20 | 华南理工大学 | 一种具有降血糖作用的巴旦木多肽及其制备方法与应用 |
| KR20250057847A (ko) | 2022-08-29 | 2025-04-29 | 일라이 릴리 앤드 캄파니 | 경구 전달용 조성물 |
| CN117417411B (zh) * | 2022-09-28 | 2025-08-29 | 广东东阳光药业股份有限公司 | Glp-1/gcg/gip三受体激动剂及其用途 |
| WO2024077149A2 (fr) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides pour la synthèse d'incrétine |
| EP4622998A2 (fr) * | 2022-11-21 | 2025-10-01 | Eli Lilly and Company | Procédé de préparation d'un double agoniste gip/glp1 |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| AU2024215381A1 (en) | 2023-01-31 | 2025-09-18 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| WO2024213022A1 (fr) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | Analogues d'incrétine et leur procédé de préparation, et utilisation |
| EP4724472A2 (fr) * | 2023-06-09 | 2026-04-15 | Sun Pharmaceutical Industries Limited | Nouveaux agonistes du récepteur double glp-1/gip et glp-1/gcg |
| AU2024305247A1 (en) | 2023-06-15 | 2025-12-11 | Novo Nordisk A/S | Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin |
| CN117024528B (zh) * | 2023-07-07 | 2024-03-22 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
| EP4745153A1 (fr) | 2023-07-14 | 2026-05-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Triagoniste des récepteurs glp-1, gip et gcg et son utilisation |
| CN122094977A (zh) * | 2023-10-26 | 2026-05-26 | 齐鲁制药有限公司 | 具有多重激动活性的多肽及其应用 |
| CN120349393A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| WO2025162423A1 (fr) * | 2024-02-02 | 2025-08-07 | 杭州先为达生物科技股份有限公司 | Triagoniste pour glp-1r, gipr et gcgr |
| TW202620038A (zh) * | 2024-06-21 | 2026-05-16 | 美商紐羅克里生物科學有限公司 | 經化學修飾之肽及其用途 |
| WO2025264809A1 (fr) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Peptides chimiquement modifiés et leur utilisation |
| WO2025264785A1 (fr) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Peptides chimiquement modifiés et leur utilisation |
| CN119978101B (zh) * | 2024-07-30 | 2025-10-10 | 四川普康药业有限公司 | 多肽化合物及其应用 |
| WO2026059846A1 (fr) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | Timbre à micro-aiguilles solubles pour administration transdermique d'un peptide |
| TW202620036A (zh) | 2024-09-27 | 2026-05-16 | 美商卡默療法股份有限公司 | 肽酪胺酸－酪胺酸（ｐｙｙ）類似物及ｇｌｐ－１ｒ促效劑之組合療法 |
| WO2026076425A1 (fr) | 2024-10-04 | 2026-04-09 | Biodrive, Inc. | Plate-forme de bioadministration orale |
| WO2026125286A1 (fr) * | 2024-12-09 | 2026-06-18 | Inventiva | Combinaisons comprenant du lanifibranor et un agoniste triple des récepteurs glp-1/gip/glucagon destinées à être utilisées dans le traitement des maladies du foie |
| WO2026125238A1 (fr) | 2024-12-10 | 2026-06-18 | Camurus Ab | Compositions et leurs méthodes d'utilisation |
| GB202418172D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
| GB202418179D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
| WO2026153399A1 (fr) * | 2025-01-15 | 2026-07-23 | 江苏恒瑞医药股份有限公司 | Composition pharmaceutique |
| CN119823233A (zh) * | 2025-03-18 | 2025-04-15 | 杭州思诺达医药科技有限责任公司 | 瑞他鲁肽的合成方法及瑞他鲁肽 |
| CN120189527B (zh) * | 2025-05-27 | 2026-04-03 | 广州富肽生物有限公司 | 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途 |
| CN120623312B (zh) * | 2025-06-26 | 2026-01-23 | 乐普健糖药业(重庆)有限公司 | Glp-1、gip、gcg三重受体激动剂及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2558842T3 (es) * | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| US8779103B2 (en) | 2009-03-27 | 2014-07-15 | Glaxo Group Limited | Drug fusions and conjugates |
| WO2011088837A1 (fr) * | 2010-01-20 | 2011-07-28 | Zealand Pharma A/S | Traitement d'états pathologiques cardiaques |
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2012153196A2 (fr) * | 2011-05-10 | 2012-11-15 | Zealand Pharma A/S | Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| AU2014345570B2 (en) * | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| CA2929459C (fr) * | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Composes agonistes doubles de gip et glp-1 et procedes associes |
| AR103242A1 (es) * | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6712323B2 (ja) * | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| EP3217027A1 (fr) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Élement de revetement large destine a entourer une tige d'ancrage |
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| AU2019309798A1 (en) * | 2018-07-23 | 2021-02-11 | Eli Lilly And Company | Method of using a GIP/GLP1 co-agonist for diabetes |
| ES3068975T3 (en) * | 2018-07-23 | 2026-06-03 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| CA3165430A1 (fr) * | 2020-01-23 | 2021-07-29 | Jorge Alsina-Fernandez | Composes co-agonistes de gip/glp1 |
| AU2024215381A1 (en) * | 2023-01-31 | 2025-09-18 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
-
2018
- 2018-12-05 TW TW112124080A patent/TWI912614B/zh active
- 2018-12-05 AR ARP180103560A patent/AR113486A1/es unknown
- 2018-12-05 TW TW107143624A patent/TWI744579B/zh active
- 2018-12-05 TW TW110136047A patent/TWI809515B/zh active
- 2018-12-14 AU AU2018388962A patent/AU2018388962B2/en active Active
- 2018-12-14 WO PCT/US2018/065663 patent/WO2019125938A1/fr not_active Ceased
- 2018-12-14 HR HRP20260186TT patent/HRP20260186T1/hr unknown
- 2018-12-14 SI SI201831298T patent/SI3727426T1/sl unknown
- 2018-12-14 CA CA3084005A patent/CA3084005C/fr active Active
- 2018-12-14 JP JP2020551786A patent/JP6961838B2/ja active Active
- 2018-12-14 FI FIEP18830618.7T patent/FI3727426T3/fi active
- 2018-12-14 MX MX2020006548A patent/MX2020006548A/es unknown
- 2018-12-14 IL IL275468A patent/IL275468B2/en unknown
- 2018-12-14 DK DK18830618.7T patent/DK3727426T3/da active
- 2018-12-14 UA UAA202002925A patent/UA129012C2/uk unknown
- 2018-12-14 KR KR1020227031761A patent/KR102622642B1/ko active Active
- 2018-12-14 RS RS20260172A patent/RS67748B1/sr unknown
- 2018-12-14 MY MYPI2020003205A patent/MY199143A/en unknown
- 2018-12-14 SG SG11202005606VA patent/SG11202005606VA/en unknown
- 2018-12-14 KR KR1020207017387A patent/KR102444783B1/ko active Active
- 2018-12-14 BR BR112020010244-0A patent/BR112020010244A2/pt unknown
- 2018-12-14 EP EP18830618.7A patent/EP3727426B1/fr active Active
- 2018-12-14 PL PL18830618.7T patent/PL3727426T3/pl unknown
- 2018-12-14 MD MDE20201098T patent/MD3727426T2/ro unknown
- 2018-12-14 CN CN201880081212.3A patent/CN111491658B/zh active Active
- 2018-12-14 SM SM20260216T patent/SMT202600216T1/it unknown
- 2018-12-14 EP EP25217077.4A patent/EP4691555A3/fr active Pending
- 2018-12-14 US US16/768,960 patent/US11542313B2/en active Active
- 2018-12-14 EA EA202091290A patent/EA202091290A1/ru unknown
- 2018-12-14 PE PE2025000913A patent/PE20251598A1/es unknown
- 2018-12-14 CR CR20200255A patent/CR20200255A/es unknown
- 2018-12-14 PT PT188306187T patent/PT3727426T/pt unknown
- 2018-12-14 LT LTEPPCT/US2018/065663T patent/LT3727426T/lt unknown
- 2018-12-14 MA MA51288A patent/MA51288B1/fr unknown
- 2018-12-14 PE PE2020000802A patent/PE20210162A1/es unknown
- 2018-12-14 ES ES18830618T patent/ES3061179T3/es active Active
- 2018-12-14 IL IL325353A patent/IL325353A/en unknown
-
2020
- 2020-05-22 CO CONC2020/0006255A patent/CO2020006255A2/es unknown
- 2020-06-02 JO JOJO/P/2020/0137A patent/JOP20200137B1/ar active
- 2020-06-17 DO DO2020000123A patent/DOP2020000123A/es unknown
- 2020-06-17 PH PH12020551025A patent/PH12020551025A1/en unknown
- 2020-06-17 CL CL2020001635A patent/CL2020001635A1/es unknown
- 2020-06-19 EC ECSENADI202032650A patent/ECSP20032650A/es unknown
- 2020-07-13 MX MX2024010201A patent/MX2024010201A/es unknown
-
2021
- 2021-10-13 JP JP2021168050A patent/JP7658877B2/ja active Active
-
2022
- 2022-11-21 US US18/057,398 patent/US12365716B2/en active Active
-
2024
- 2024-09-23 US US18/893,357 patent/US12371465B2/en active Active
-
2025
- 2025-02-26 JP JP2025029445A patent/JP2025093970A/ja active Pending
- 2025-06-23 US US19/245,761 patent/US20250313605A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3817822A4 (fr) | Agents de dégradation de protéines et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| PL3727426T3 (pl) | Analogi inkretyny i ich zastosowania | |
| EP3749318A4 (fr) | Raltitrexed gamma-polyglutamaté et utilisations associées | |
| EP3749315A4 (fr) | Raltitrexed alpha-polyglutamaté et utilisations associées | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3445365A4 (fr) | Inhibiteurs d'ezh2 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3749314A4 (fr) | Méthotrexate alpha-polyglutamaté et utilisations associées | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| EP2968443A4 (fr) | Analogues d'hepcidine et leurs utilisations | |
| EP3439741A4 (fr) | Antagonistes d'alk7 et leurs utilisations | |
| EP3283516A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations |